|Bid||29.56 x 1000|
|Ask||35.68 x 900|
|Day's Range||31.98 - 33.00|
|52 Week Range||19.35 - 42.28|
|Beta (5Y Monthly)||1.00|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov. 05, 2020 - Nov. 10, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||45.73|
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that company management will participate in three upcoming conferences:
XNCR earnings call for the period ending July 31, 2020.
Xencor (XNCR) delivered earnings and revenue surprises of -8.93% and 43.47%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?